retatrutide mechanism gip glp-1 glucagon triple agonist Cagrilintide vs Compared ADA 2026: Retatrutide Revolution

Phase 3 trial data documented 28.7% average weight loss with retatrutide 12mg versus 14.9% with semaglutide 2.4mg, though these come from different trials with different populations

Fatigue may occur because the body is adjusting to treatment, but it may also reflect under-eating, low protein intake, dehydration, electrolyte changes, rapid weight loss, poor sleep, constipation, low blood sugar, low blood pressure, or another medical issue

Telehealth programs like MEDVi and TrimRx bundle your prescription, clinician review, medication, and delivery into a single monthly fee, making them one of the most cost-effective and straightforward routes to access

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes